Canterbury DHB


Prevention of Menorrhagia

The prevention of menstrual bleeding during therapy induced thrombocytopenia requires specific treatment. The use of LHRH analogues has been shown to be less likely to cause VOD than progestogens like norethisterone in allogeneic BMT recipients. Leuprorelin depot at a dose of 3.75 mg SC should be administered at least 30 days before conditioning, and is repeated every 4 weeks while severe thrombocytopenia persists. For non-allogeneic intensively treated patients, menstruation should be suppressed by norethisterone 5 mg TDS PO. Some evidence supports the use of Leuprorelin to "shield" the ovaries from the effects of chemo and radiotherapy and increase the chance of ovarian recovery.

About this Canterbury DHB document (8765):

Document Owner:

Sean Macpherson (see Who's Who)

Last Reviewed:

January 2019

Next Review:

January 2022


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 8765